1. Home
  2. CDXS vs IMMP Comparison

CDXS vs IMMP Comparison

Compare CDXS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDXS
  • IMMP
  • Stock Information
  • Founded
  • CDXS 2002
  • IMMP 1987
  • Country
  • CDXS United States
  • IMMP Australia
  • Employees
  • CDXS N/A
  • IMMP N/A
  • Industry
  • CDXS Major Chemicals
  • IMMP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CDXS Industrials
  • IMMP Health Care
  • Exchange
  • CDXS Nasdaq
  • IMMP Nasdaq
  • Market Cap
  • CDXS 216.6M
  • IMMP 251.8M
  • IPO Year
  • CDXS 2010
  • IMMP N/A
  • Fundamental
  • Price
  • CDXS $2.65
  • IMMP $2.07
  • Analyst Decision
  • CDXS Buy
  • IMMP Buy
  • Analyst Count
  • CDXS 2
  • IMMP 1
  • Target Price
  • CDXS $11.00
  • IMMP $7.00
  • AVG Volume (30 Days)
  • CDXS 542.5K
  • IMMP 179.0K
  • Earning Date
  • CDXS 10-30-2025
  • IMMP 10-10-2025
  • Dividend Yield
  • CDXS N/A
  • IMMP N/A
  • EPS Growth
  • CDXS N/A
  • IMMP N/A
  • EPS
  • CDXS N/A
  • IMMP N/A
  • Revenue
  • CDXS $57,164,000.00
  • IMMP $3,306,742.00
  • Revenue This Year
  • CDXS $12.88
  • IMMP $16.82
  • Revenue Next Year
  • CDXS $21.64
  • IMMP N/A
  • P/E Ratio
  • CDXS N/A
  • IMMP N/A
  • Revenue Growth
  • CDXS N/A
  • IMMP 31.28
  • 52 Week Low
  • CDXS $1.90
  • IMMP $1.32
  • 52 Week High
  • CDXS $6.08
  • IMMP $2.71
  • Technical
  • Relative Strength Index (RSI)
  • CDXS 55.26
  • IMMP 64.75
  • Support Level
  • CDXS $2.46
  • IMMP $1.92
  • Resistance Level
  • CDXS $2.76
  • IMMP $2.28
  • Average True Range (ATR)
  • CDXS 0.16
  • IMMP 0.11
  • MACD
  • CDXS 0.02
  • IMMP 0.02
  • Stochastic Oscillator
  • CDXS 50.97
  • IMMP 59.43

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Share on Social Networks: